The American Journal of Psychiatry’nin Temmuz 2013 sayısında yayınlanan bir makalede, sosyal anksiyete bozukluğu hastalarında bilişsel davranışçı terapiye D-Sikloserin eklenmesi ile plasebo eklenmesi arasında yanıt ve remisyon oranları açısından anlamlı bir farklılık bulunmadığı belirtildi. Makalenin özetini ve linkini ilginize sunuyoruz.– TürkPsikiyatri |
D-Cycloserine as an Augmentation Strategy With Cognitive-Behavioral Therapy for Social Anxiety Disorder
Objective The authors examined whether d-cycloserine, a partial agonist at the glutamatergic N-methyl-d-aspartate receptor, augments and accelerates a full course of comprehensive cognitive-behavioral therapy (CBT) in adults with generalized social anxiety disorder.
Method This was a multisite randomized placebo-controlled efficacy study with 169 medication-free adults with generalized social anxiety disorder, of whom 144 completed the 12-week treatment and 131 completed the three follow-up assessments. Patients were randomly assigned to receive 50 mg of d-cycloserine or placebo 1 hour before each of five exposure sessions that were part of a 12-session cognitive-behavioral group treatment. Response and remission status was determined at baseline, throughout treatment, at end of treatment, and at 1-, 3-, and 6-month follow-up assessments by assessors who were blind to treatment condition.
Results d-Cycloserine-augmented and placebo-augmented CBT were associated with similar completion rates (87% and 82%), response rates (79.3% and 73.3%), and remission rates (34.5% and 24.4%) at the posttreatment assessment; response and remission rates were largely maintained at the follow-up assessments. Although d-cycloserine was associated with a 24%–33% faster rate of improvement in symptom severity and remission rates relative to placebo during the treatment phase, the groups did not differ in response and remission rates.
Conclusions d-Cycloserine did not augment a full course of comprehensive CBT for social anxiety disorder.